Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Hepatocellular carcinoma (HCC) is a prevalent cancer with unsatisfactory treatment outcomes.
• Pharmacological inhibition of mammalian target of rapamycin (mTOR) shows promise for HCC regression.

Purpose of the Study:

• To develop a novel self-assembling nanoblocker for enhanced mTOR inhibition in HCC.
• To evaluate the anti-tumor efficacy and immune-modulating effects of the nanoblocker in preclinical HCC models.

Main Methods:

• Conjugation of AZD8055 (mTORC1/2 blocker) with unsaturated fatty acids to form self-assembling nanoblockers.
• In vitro evaluation against HCC cells and in vivo studies using orthotopic and subcutaneous HCC mouse models.

Main Results:

• Linoleic acid-conjugated nanoblocker (AZD NB) showed optimal properties and pharmacokinetic optimization.
• AZD NB significantly suppressed tumor outgrowth in multiple HCC models.
• AZD NB increased intratumoral CD8+ T cell infiltration and memory T cell populations, suggesting immune microenvironment remodeling.

Conclusions:

• Chemically engineered mTOR nanoblockers enhance anti-tumor efficacy compared to the free drug, potentially improving HCC patient survival.
• This nanosystem serves as a versatile platform for synergistic drug delivery.